Articles tagged with Gpcr Pathway
Researchers discover molecules that can rewire G protein-coupled receptor signaling, turning busy receptors into precision tools. The findings hold promise for new treatments with fewer side effects.
Researchers have discovered that ascidians measure time to adulthood by accumulating cyclic adenosine monophosphate (cAMP), ensuring a reliable timing of metamorphosis. The study's findings provide insights into time-measurement mechanisms in other organisms and may aid in aquaculture and marine biofouling control.
A new study reveals that specific gut bacteria can break down certain drugs, altering their efficacy. The research found that 30 out of 127 tested drugs were heavily metabolized by human gut microbiota, potentially reducing their effectiveness. The study's findings could have significant implications for personalized medicine and drug ...
Researchers have identified new gateways for drugs to modulate proteins regulating cellular activity. These discoveries may facilitate the creation of new medications or improve existing ones, leading to more targeted therapies and reduced side effects.
Researchers at UChicago captured complete images of adhesion G protein-coupled receptors, revealing their complex extracellular region's interaction with the transmembrane region. The findings suggest alternative means of activating the receptor without separating the GAIN domain.
Researchers at Stanford University have developed a new synthetic receptor, PAGER, that can accommodate a broader range of inputs and produce a more diverse set of outputs. The tool enables control of neuronal activity, immune responses, and therapeutic treatments in lab experiments.
Researchers deciphered how the β2 adrenergic receptor transmits signals at an atomic level, revealing its three-dimensional structure and biochemical cascades. The study provides new insights into G-protein coupling and may lead to improved drug development for obesity research.
Researchers have identified a novel target downstream of parathyroid hormone signaling that suppresses bone formation. Gprc5a negatively regulates osteoblast proliferation and differentiation by partially suppressing BMP signaling, potentially increasing teriparatide effectiveness in non-responding patients.
A team of researchers at University of California San Diego has identified a biochemical mechanism that can interrupt cellular communication chains, disrupting the signaling pathways related to many diseases. The discovery highlights the importance of growth factors and G protein-coupled receptors in cell signaling.
A new study has identified two proteins that play a vital role in modulating cell responses in schizophrenia. The researchers found that these proteins can be targeted to develop drugs that address specific symptoms of the disease, potentially leading to more effective and personalized treatments.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Researchers have identified a new regulator of eating behavior, the latrophilin 1 receptor, which is linked to obesity. The receptor, primarily studied for its role in synapse formation, was found to be present in brain regions controlling food intake and adipose tissue.
The study reveals how opioid receptors stabilize a state for effective signal transmission, making superagonists potent and dangerous. It also highlights the importance of understanding molecular interactions for drug development and developing safer medicines.
Researchers at UNC School of Medicine discovered the detailed protein structure of the TAS2R14 bitter taste receptor, revealing how it identifies and activates bitter tastants. The discovery has potential applications in drug development for metabolic diseases like obesity and diabetes.
Researchers identified a novel bicarbonate-sensing GPCR, GPR30, that regulates reperfusion injury in ischemic stroke. GPR30 deficiency showed significant protection against cerebral ischemia-reperfusion injury.
Scientists at St. Jude Children's Research Hospital have discovered that only about 80 amino acids in the β2-adrenergic receptor contribute to its pharmacological properties, with specific residues controlling efficacy and potency. Understanding these molecular origins can help design more potent and efficacious drugs.
Scientists at Medical College of Wisconsin create biased agonists that reduce hallucinogenic effects while preserving therapeutic potential. These compounds, designed to selectively activate serotonin receptors, show promise in treating depression and other mental health conditions.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
Researchers have observed beta-arrestin molecules directly controlling receptor-mediated signals in living cells using advanced microscopy. The study reveals a new mechanism of how these proteins interact with receptors on the plasma membrane, enabling efficient control of signal flow and desensitization.
Researchers at UNIGE discovered that natural opioids cannot enter cells, whereas therapeutic opioids can, leading to differences in physiological responses. The study's findings could help develop safer medications with improved efficacy and reduced side effects.
Researchers have identified a common amino acid, glycine, as a potential trigger for major depression, anxiety, and other mood disorders. The discovery improves understanding of the biological causes of major depression and could accelerate efforts to develop new medications.
Researchers at Johns Hopkins Medicine discover that nasal cell receptors activate few G protein molecules to produce a signal, contradicting the mainstream idea of high amplification. The study found that the probability of an odorant receptor activating just one G protein is 1 in 10,000, supporting weak signaling.
A new study found that neuronal cilia play a crucial role in ensuring proper signaling of dopamine receptors, which regulate motivated behavior and movement. Mice lacking functional cilia on dopamine receptor 1-expressing neurons became obese and sedentary, highlighting the importance of cilia in dopamine-dependent neural signaling.
Researchers have identified a molecular mechanism behind worm olfaction, revealing how they discriminate between over 1,300 scents despite having only 32 olfactory neurons. The discovery involves the conserved protein arrestin, which helps fine-tune multiple sensations in both worms and humans.
Researchers used single-molecule imaging to study GPCR activation, gaining insight into cellular signal relay and potential drug targets for various disorders. The findings show that the receptor tail plays an autoinhibitory role, controlled by agonist binding, which affects signaling intensity and duration.
Scientists have found complex signaling pathways in cells, using a technique called fluorescence microscopy to visualize nanodomains beneath the cell membrane. These domains can be thought of as pop-up factories that process signals from receptors on the cell surface.
A Tel Aviv University study found a significant link between changes in G-protein-coupled receptors and brain adaptability. Disabling the voltage sensor of these proteins caused uncontrolled brain flexibility, leading to excessive habituation to odors.
Researchers at PSI have developed a platform to measure biased signalling in G protein-coupled receptors (GPCRs), enabling selective therapeutic effects and fewer side effects. By testing specially designed bivalent ligands, they can bias signalling towards desired pathways.
A University of South Florida Health-led team discovered a lead candidate that selectively relaxes airway smooth muscle cells with no detectable drug desensitization. The biased beta-agonist, C1-S, offers a therapeutic option for asthma and obstructive lung diseases without the rapid loss of effectiveness seen with traditional β-agonists.
A recent study reveals that protein HSP27 plays a crucial role in regulating blood vessel leakage, which is a hallmark of sepsis. By targeting HSP27, researchers hope to develop drugs that can stabilize blood vessel barriers and prevent fluid loss.
Scientists have discovered how neurotransmitters and proteins interact to trigger neuronal responses in the brain, with implications for understanding mood disorders and addictions. The study reveals small changes in protein connections control cellular responses, enabling precise regulation of neurotransmitter effects.
Researchers have developed a new imaging technique that captures individual receptors on the surface of living cells with unprecedented detail. This breakthrough could lead to a new generation of drugs with greater specificity and reduced side effects, particularly for disorders such as schizophrenia and depression.
Researchers at Duke University developed a synthetic molecule that selectively dampens cocaine-induced hyperactivity and interferes with dopamine metabolism in the brain's rewards center. The treatment slowed down drug use by 20 minutes to an hour and reduced consumption by over 80 percent in mice.
Researchers at MIPT have developed a method to combine structural and spectroscopic approaches for studying membrane receptors. This allows for a detailed understanding of receptor functioning and behavior inside the cell, which is crucial for developing effective drugs.
Scientists have shed light on the structure and functioning mechanism of CysLT receptors, regulating inflammatory responses associated with allergic disorders. The study identified critical ligand-binding determinants, enabling better understanding of receptor-ligand complexes and potential drug targets.
Researchers develop computational method to predict and design allosteric functions in proteins, enabling the creation of novel signaling receptors with precise functions. They successfully designed and repurposed a dopamine receptor into a serotonin biosensor, demonstrating the potential for this approach in personalized medicine.
Researchers at Cornell University have solved the three-dimensional structure of a protein complex involved in vertebrate vision at atomic resolution, revealing how signals from photons are amplified in the eye. The study provides insights into G-protein-coupled receptors and their role in human vision, with potential implications for ...
The study uncovered several hundred coupling events between GPCRs and G-proteins, greatly expanding the understanding of how these receptors work. This new data enables better prediction of GPCR-G-protein coupling and potential design of artificial GPCRs with specific signalling properties.
Researchers outline detailed sequence of events where a GPCR encounters its downstream signaling partner, providing insights into fundamental mechanisms of drug-induced signaling. The new analysis technique can identify precise amino acids most central to GPCR function, enabling potential sites for precision drug targeting.
The study reveals that both melatonin receptors contain narrow channels allowing melatonin to pass through, blocking serotonin. This knowledge enables the design of safer and more effective drugs to target specific receptors, such as MT1, which has been challenging to develop.
Researchers have developed 3D models of the two melatonin receptors, MT1 and MT2, which will help design drugs that interact only with these receptors, reducing side effects. The findings could lead to new treatments for sleep disorders, diabetes, cancers, and other health issues affected by melatonin.
Researchers at UToledo discovered that statins can suppress a biological process disrupting cardiac function, potentially altering bodily functions controlled by G protein-coupled receptors. Statins also reduce the ability of migratory cells, such as cancer and immune cells, to travel.
Scientists at the University of Würzburg have developed a new method called BRET that allows them to test the activity and potency of G protein-coupled receptor (GPCR) ligands in living cells. This breakthrough enables faster discovery of novel pharmaceutical substances with less side effects.
Researchers discovered a llama-derived nanobody that specifically targets G beta-gamma signaling, preventing it from activating several other signaling proteins. This approach may provide control over multiple GPCRs and avoid undesired cellular events.
Researchers have discovered that cells' G protein-coupled receptor signaling systems can pass more than 2 bits of information per interaction with external stimuli, exceeding previous estimates. This finding has crucial implications for biology and drug discovery, particularly in the development of novel anti-cancer agents.
A recent study by Johns Hopkins researchers found previously known skin itch receptors in the airways of mice, which appear to contribute to bronchoconstriction and airway hypersensitivity. The discovery may be a promising new target for developing drug therapies for asthma and other respiratory disorders.
Researchers have discovered that G protein-coupled receptors (GPCRs) are active in the cell interior, influencing gene transcription and cell division. This finding has implications for developing innovative drugs targeting receptor function or uptake.
Researchers have developed a new technique that allows for precise mapping of cellular signaling networks involved in human biology and disease. This breakthrough opens up exciting avenues for understanding and treating psychiatric diseases, including opioid addiction.
USC scientists discovered unexpected characteristics of the AT2 protein, which interacts with the angiotensin II hormone regulating blood pressure. The study reveals potential new paths to drugs controlling cardiovascular disease and pain, offering an important first step towards targeted therapies.
Researchers are studying how receptors are transported from inside the cell to the surface where they function. Small proteins like Rab43 play a crucial role in this process, helping to ensure the proper functioning of GPCRs.
A new study reveals that cholesterol selectively binds to specific regions of GPCR proteins, enabling them to form paired structures and sense external signals. This discovery could open up new avenues for drug discovery and understanding cancer metastasis and AIDS.
Researchers at Duke Health have discovered a new paradigm for how G protein-coupled receptors activate cell signaling mechanisms. The formation of 'mega-plexes' explains how signals can continue to be sent after internalization, opening up possibilities for targeted drug therapies.
Temple researchers have uncovered a new mechanism by which aldosterone triggers heart damage, involving GRK2 and GRK5 signaling molecules. The study found that inhibiting these kinases could provide a potential therapeutic solution for heart failure.
The Scripps Research Institute (TSRI) team has discovered a unique anti-diabetes compound that activates the GLP-1 receptor's G-protein pathway, potentially leading to a new type of diabetes treatment. The novel molecule P5 shows promise in boosting glucose tolerance with minimal insulin stimulation.
Dr. Lefkowitz's research reveals that all GPCRs share the same structure, enabling the development of more effective and safer drugs for various pathologies including type 2 diabetes and obesity.
Researchers used X-ray crystallography to visualize the structure of a neurotensin receptor, shedding light on its mechanism. Binding of neurotensin to the receptor triggers critical conformational changes that activate G protein-coupled signaling pathways.
Researchers have elucidated the structure of two adiponectin receptors, revealing a completely new type unlike G protein-coupled receptors. The discovery may lead to new adiponectin receptor agonists for treating obesity-related diseases like type 2 diabetes.
Scientists used computer modeling to trace water channels in cell surface receptors (GPCRs), discovering their role in signal transduction. The study suggests that targeting these internal water pathways could lead to the development of more efficient drugs.
A researcher is using a $900,000 grant to resolve the debate on whether G protein-coupled receptors form dimers. He suspects that light transfer between constantly moving receptors may be random and not actual relationships. The study aims to find out how many drug targets are there and if they can help in treating various ailments.